Cysteine ( DrugBank: Cysteine )

---

10 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3
19	ライソゾーム病	1
34	神経線維腫症	1
84	サルコイドーシス	1
85	特発性間質性肺炎	2
88	慢性血栓塞栓性肺高血圧症	1
90	網膜色素変性症	1
254	ポルフィリン症	2
296	胆道閉鎖症	1
310	先天異常症候群	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05122559 (ClinicalTrials.gov)	November 2021	8/11/2021	Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis	Randomized Controlled Trial of N-acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive	Drug: N-acetyl cysteine;Drug: Placebo	Emmanuelle Waubant	United States Department of Defense	Not yet recruiting	40 Years	70 Years	All	98	Phase 2	NULL
2	NCT02804594 (ClinicalTrials.gov)	October 1, 2016	3/6/2016	A Study of Oxidative Pathways in MS Fatigue	A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis;Fatigue	Drug: N-acetyl cysteine;Drug: Placebo	University of California, San Francisco	NULL	Completed	18 Years	75 Years	All	15	Phase 2	United States
3	EUCTR2008-000955-90-IT (EUCTR)	24/04/2007	12/03/2008	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	multiple sclerosis MedDRA version: 9.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive	Product Name: n-acetylcysteine INN or Proposed INN: Acetylcysteine	ISTITUTO C. MONDINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

19. ライソゾーム病

---

臨床試験数 : 899 /  薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01614431 (ClinicalTrials.gov)	March 2011	19/5/2012	N Acetyl Cysteine for Cystinosis Patients	N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients	Renal Disease;Cystinosis	Drug: N acetyl cysteine	University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Completed	1 Year	18 Years	Both	23	Phase 4	NULL

34. 神経線維腫症

---

臨床試験数 : 133 /  薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04481048 (ClinicalTrials.gov)	December 15, 2020	15/5/2020	Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1	Antioxidant Therapy With N-acetylcysteine for Motor Behavior and/or Learning in Children With Neurofibromatosis Type 1	Neurofibromatosis 1	Drug: N-Acetyl cysteine;Other: Placebo	Children's Hospital Medical Center, Cincinnati	United States Department of Defense	Recruiting	8 Years	16 Years	All	58	Phase 2	United States

84. サルコイドーシス

---

臨床試験数 : 149 /  薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01587001 (ClinicalTrials.gov)	November 2011	10/1/2012	The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis	The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis	Pulmonary Sarcoidosis	Dietary Supplement: N-acetyl-cysteine;Drug: Placebo	National Jewish Health	American Thoracic Society	Completed	18 Years	80 Years	All	17	N/A	United States

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03720483 (ClinicalTrials.gov)	January 2022	18/7/2018	Inhaled NAC in Treatment of IPF	Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Drug: N-acetyl cysteine then Placebo;Drug: Placebo then N-acetyl cysteine	University of Colorado, Denver	NULL	Withdrawn	40 Years	75 Years	All	0	Phase 1/Phase 2	United States
2	NCT04300920 (ClinicalTrials.gov)	December 17, 2020	6/3/2020	Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial	Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial	Idiopathic Pulmonary Fibrosis	Drug: N-acetyl cysteine;Drug: Placebo	Weill Medical College of Cornell University	University of Virginia;University of Michigan;Pulmonary Fibrosis Foundation;University of Washington;National Heart, Lung, and Blood Institute (NHLBI);Three Lakes Foundation	Recruiting	40 Years	N/A	All	200	Phase 3	United States

88. 慢性血栓塞栓性肺高血圧症

---

臨床試験数 : 157 /  薬物数 : 107 - (DrugBank : 22) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04081012 (ClinicalTrials.gov)	May 21, 2019	16/8/2019	N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Chronic Thromboembolic Pulmonary Hypertension.	N-acetyl Cysteine in Post-reperfusion Pulmonary Injury in Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Balloon Angioplasty and Pulmonary Endarterectomy.	Chronic Thromboembolic Pulmonary Hypertension	Drug: N-acetyl cysteine;Drug: Placebo	Instituto Nacional de Cardiologia Ignacio Chavez	NULL	Recruiting	N/A	N/A	All	34	N/A	Mexico

90. 網膜色素変性症

---

臨床試験数 : 147 /  薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03063021 (ClinicalTrials.gov)	February 15, 2017	16/2/2017	The FIGHT-RP1 Study	A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)	Retinitis Pigmentosa	Drug: N-Acetyl Cysteine (NAC)	Johns Hopkins University	NULL	Completed	18 Years	N/A	All	30	Phase 1	United States

254. ポルフィリン症

---

臨床試験数 : 72 /  薬物数 : 53 - (DrugBank : 16) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00004831 (ClinicalTrials.gov)	October 1996	24/2/2000	Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria		Erythropoietic Protoporphyria	Drug: cysteine hydrochloride	FDA Office of Orphan Products Development	St. Luke's-Roosevelt Hospital Center	Completed	18 Years	65 Years	Both	20	N/A	NULL
2	NCT00004940 (ClinicalTrials.gov)	May 1996	24/2/2000	Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria		Erythropoietic Protoporphyria	Drug: cysteine hydrochloride	Brigham and Women's Hospital	NULL	Completed	18 Years	65 Years	Both	50	Phase 3	NULL

296. 胆道閉鎖症

---

臨床試験数 : 71 /  薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03499249 (ClinicalTrials.gov)	May 18, 2018	4/4/2018	N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy	A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy	Biliary Atresia	Drug: N-Acetyl cysteine	Baylor College of Medicine	NULL	Active, not recruiting	0 Days	90 Days	All	16	Phase 2	United States

310. 先天異常症候群

---

臨床試験数 : 11 /  薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04381897 (ClinicalTrials.gov)	June 1, 2023	6/5/2020	Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome	Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study	Cornelia de Lange Syndrome	Drug: N-acetyl cysteine;Other: Placebo	Johns Hopkins University	Cornelia de Lange Syndrome Foundation	Not yet recruiting	13 Years	35 Years	All	10	Phase 2	United States

先頭へ